Delisting from the Australian Securities Exchange (ASX)
On 11 October 2023, Kazia Therapeutics announced its intention to delist from the Australian Securities Exchange (ASX).
Following careful consideration, the Kazia Board has ultimately determined that the costs, administrative burden and commercial disadvantages of remaining listed on ASX outweigh any benefits of a continued ASX listing. Following the Delisting, the Company will maintain its listing on the NASDAQ and the fully paid ordinary shares in the Company (Shares) will no longer be quoted on the ASX.
Interview with Kazia CEO Dr John Friend regarding the Company’s intention to delist from the ASX
Resources for shareholders
An announcement setting out the background to the delisting application is listed below. This Announcement provides additional information on the rationale for the decision to de-list from the ASX. There is also information about how shareholders who hold ordinary unlisted shares (that is those shareholders who did not convert their Kazia shares to ADSs prior to the ASX de-listing) can now convert their shares to ADSs.
Who can I contact for more information?
If you have a question in relation to the Delisting or any information set out in this letter please contact your tax advisor or info@kaziatherapeutics.com.
If you would like to subscribe to receive email alerts for Company news, including SEC announcements and media releases, please complete the form here.
